GPP3 Guidelines, 2015

GPP3 is an update of the original Good Publication Practice (GPP) guidelines, which were originally published in 2003 and updated for the first time in 2009. The ISMPP GPP3 Steering Committee has now brought the 2009 version of the guidelines for good publication practice (GPP2) up to date to increase the focus on integrity and transparency in industry-sponsored publication planning and development in today’s environment.

In July 2016, GPP3 was translated into the Chinese language. In April 2019, GPP3 was translated into the Japanese language. Their availability serves to expand the reach of GPP3 to other regions in the world in an effort to broaden the adoption of the publication practices included in GPP3 and extend the focus on transparency and integrity of medical publications.

The Committee’s work, Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3, was independently peer reviewed and published: Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461-464; doi:10.7326/M15-0288

Click here to access the abstract from the Annals of Internal Medicine.

Click here
to access the full article in the Annals of Internal Medicine.

New areas addressed in GPP3 include:

  • Guidance on the most recent ICMJE authorship criteria (2013)

  • Common issues regarding authorship

  • Improved clarity on author payment and reimbursement

  • Clarification as to what constitutes ghost writing or guest authorship

  • The role and benefit of professional medical writers

  • Guidance for appropriate data sharing.

Supporting Materials

Frequently Asked Questions 

GPP3 presentation by Teresa Peña, PhD

Presentation by Liz Wager offering her perspective on the evolution of GPP and key changes in GPP3

Editorial from International Journal of Clinical Practice by Leslie Citrome, MD MPH

Overview of Good Publication Practice Guidelines, Including GPP3: Why should medical writers care? Presented by Teresa Peña at AMWA 2015

GPP3 has received endorsement from a number of organizations and professional associations.

GPP Historical Archive

GPP2 Guidelines, 2009

To address legislative, guidance, and ethical developments since 2003, and to reinforce the aims of the original 2003 publication, the International Society for Medical Publication Professionals (ISMPP) convened a Steering Committee to develop a revised Good Publication Practice document which is now known as “GPP2”.

The Committee’s work, GPP2, was independently peer reviewed and published:

Graf C, Battisti WP, Bridges D, et al. for the International Society of Medical Publication Professionals. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330.

BMJ article online

PDF of BMJ article 

GPP2 webpage

GPP Guidelines, 2003

The landmark guidelines on Good Publication Practice (GPP) published in 2003 were developed with the aim of ensuring that “clinical trials sponsored by pharmaceutical companies are published in a responsible and ethical manner."

Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Curr Med Res Opin 2003;19:149-154. 
PubMed link  or PDF of CMRO article

Click here to read the Editorial that accompanied the original GPP

Click here to view the GPP Working Group

Click here for background notes on GPP


GPP3 Frequently Asked Questions

GPP3 Article in Annals
Click here

Click here

GPP3 Steering Committee
Click here

GPP3 Website Committee
Click here

GPP3 press release
Click here

Contact GPP3
[email protected]

Reprint Information
Click here




Endorsements & Support

The following organizations support and encourage use of the Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3 guidelines.



Back to top